Answers are grounded in this paper and cite their sources.
BACKGROUND: Tanzania is one of the countries confronting a multidrug-resistant tuberculosis (MDR-TB) epidemic. RESEARCH: Research studies on drug susceptibility testing (DST) for second-line TB drugs given to Tanzanian MDR-TB patients has demonstrated mycobacterial resistance to important MDR-TB drugs, such as ethionamide, ofloxacin, amikacin, kanamycin, and pyrazinamide. Likewise, pharmacokinetic studies have shown a high frequency of patients with circulating serum drug levels below the expected ranges, especially for levofloxacin and kanamycin - key drugs in MDR-TB treatment that also affect ex-vivo plasma drug activity. RECOMMENDATIONS: genotypic results to optimize MDR-TB treatment. Quantitative drug susceptibility can guide the selection of options for second-line anti-TB drugs. The TB drug assay, an alternative biomarker for therapeutic drug monitoring, can identify patients who have extensively drug-resistant TB or are exposed to suboptimal serum drug levels of, specifically, levofloxacin and kanamycin.
No takes yet. Share an insight, caveat, or question.
Stellah Mpagama (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: